RA, Psoriasis Meds May Up Risk of Hep B Flares
SAN FRANCISCO, CA—Biologic agents are associated with “significantly higher” risk of hepatitis B virus (HBV) flares than non-biologic disease-modifying antirheumatic drugs (nbDMARDs) among patients with rheumatoid arthritis (RA) or psoriasis, according to a study reported at The Liver Meeting® 2015.
“The emergence of biologic therapies in the management of inflammatory bowel diseases, autoimmune rheumatic, and dermatologic diseases has raised concerns about the risks of HBV flares, particularly among anti-tumor necrosis factor (TNF) therapy users,” noted lead study author Chun-Ying Wu, MD, PhD, MPH, of the Division of Gastroenterology, Taichung Veterans General Hospital and National Yang-Ying University, Taichung, Taiwan.
Dr. Wu and colleagues conducted a population-based cohort study to determine whether anti-TNF agents are associated with increased HBV hepatitis flare risk than nbDMARDs, using data from the Taiwan National Health Insurance Research Database for patients with HBV infection who were diagnosed with RA or psoriasis.
A total of 354 patients were identified who had received TNF-α antagonists; these patients represented the study's biologics cohort. They were matched by baseline characteristics and propensity scores 1:2 with 708 patients who received nbDMARDs alone (DMARDs cohort). Each cohort was followed up for HBV flares.
“The 5-year cumulative incidences of HBV hepatitis flare were 19.3% (95% confidence interval [CI] 13.8–24.9) and 12.9% (95% CI 9.2–16.6) for the biologics and DMARDs cohorts, respectively (P=0.004),” Dr. Wu reported. Patients in the biologics cohort had significantly higher risk of HBV hepatitis flare (adjusted hazard ratio [HR] 2.10, 95% CI: 1.3, 3.3; P<0.001).
The higher risk of hepatitis flare in users of TNF-α antagonists was consistently found in all subgroups, Dr. Wu noted. Subgroups included age, gender, RA, diabetes mellitus, hypertension, hyperlipidemia, COPD, disease duration, methotrexate, retinoids, cyclosporine, prednisolone, silymarin, phototherapy, and arheuma.